Regulatory Cooperation and Reliance

For a trade whose business has sustained decades of respectable growth and margins. The novel Regulatory aspects include Novel Drug Delivery Systems, Medical Affairs, Active Pharmaceutical Ingredients, and Licensing in pharmaceutical production, packaging materials and pharmaceutical excipients. The new setting is testing the resilience and ingenuity of company corporations across the world. Some business models lack the ability to survive the approaching finish of the “blockbuster drug” era, even whereas resource constraints and sluggish innovation hinder the event of recent capabilities required to thrive in a very apace evolving market. These square measure so tumultuous times for the U.S. company trade. Succeeding in a very shifting world market and evolving tending landscape would require pharmaceutical corporations to adopt innovative business models targeted on novel ways, including: stress on “economic” outcomes: additional attention to the “economic value” of a medical care as a determinant for analysis funding and development. Personalised medicine: Shifting from “blockbuster drugs” to “personalized health and wellbeing.” Externalization and collaboration: additional reliance on external partners, academia, trade consortia and entrepreneurs for innovation, productivity and world growth. Globalization: fast growth to for countries for scientific talent and new markets. Health IT adoption: finance in new technologies to modify innovation and drive efficiencies. Novel Regulatory strategies include both Nano therapeutics and biotech therapeutics.

Pharmaceutical and drug registration is also becoming more regulated throughout Asia. Indeed, the requirements for local drug clinical trials are becoming more prevalent in some countries like Korea and Taiwan. With innovation key to growth in emerging markets, regulatory policies are becoming more open and supportive of innovative drugs. There are several challenges around pharmacovigilance in Asia. India plans to begin interacting with international pharmacovigilance bodies in 2013/14  by which time it will be among the biggest pharmaceutical markets in the world before creating an Asia-Pacific centre of excellence for pharmacovigilance in 2014/15.The complicated regulatory landscape in Asia can be a barrier to success for foreign companies that do not have the experience or resources that are essential to overcome the obstacles in countries such as China, India, Japan, Korea and Taiwan

  • Product Registration & Submission
  • Accelerating Drug Approval Timelines
  • Drug Pricing Mechanisms
  • Improving Drug and Vaccine Safety
  • Dealing with Higher Registration and Renewal Fees

Related Conference of Regulatory Cooperation and Reliance

Januray 19 2016

Basics of Pharmaceutical Regulatory Affairs

London UK
January 17-19 2016

Global Best Practices Conference

Dallas USA
January 28-29 2016

PCC 2016 - CBI s 13th Annual Pharmaceutical Compliance Congress

Alexandria USA
February 17-18 2016

Regulatory Strategy for Established Active Substances

Chesham UK
February 24-28 2016

Basics of Medical Devices Regulatory Affairs

London UK
February 4-5 2016

2nd Annual Food Labeling Evolving Regulatory Compliance Conference

Arlington USA
March 28-31 2016

Pharmaceutical regullatory summit 2016

Shanghai China
March 3-4 2016

Marketing Pharmaceuticals 2016

North Bethesda USA

Basics of Pharmaceutical Regulatory Affairs

London UK
April 13-15 2016

The US Regulatory Environment

Chesham UK
April 28-30 2016

Basics of Pharmaceutical Regulatory Affairs

London UK
May 18-19 2016

CRED Clinical Trials

London UK
May 21 - 24 2017

6th Pharmaceutical Sciences World Congress PSWC 2017

Stockholm Sweden
May 21-22 2016

World Health Professions Conference on Regulation 2016

Geneva Switzerland
June 16-18 2016

CRED SmPC Patient Information Leaflet Labelling

London UK
June 6-8 2016

CRED Variations

London UK

Basics of Pharmaceutical Regulatory Affairs

London UK
August 28-September 01 2016

World Congress of Pharmacy and Pharmaceutical Sciences 2016

Buenos Aires Argentina
August 8-9 2016

ICPRA 2016 18th International Conference on Pharmaceutical Regulatory Affairs

Venice Italy

Regulatory Cooperation and Reliance Conference Speakers